SCHEMBL7042944

SCHEMBL7042944

COC(=O)Cc1ccc(SC(=O)N(C)C)c(Cl)c1Cl

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 1/20 0.35
ALDH1A1 P00352 5/20 0.33
GAA P10253 2/20 0.33
GFER P55789 1/20 0.33
CYP4F2 P78329 1/20 0.33
CYP4A11 Q02928 1/20 0.33
TSHR P16473 1/20 0.32
HSP90AB1 P08238 1/20 0.31
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
HPGD P15428 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
TP53 P04637 1/20 0.31
POLB P06746 1/20 0.31
KDM4E B2RXH2 3/20 0.31
EGFR P00533 1/20 0.31
GLA P06280 1/20 0.31
KMT2A Q03164 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6137059 0.84 CXCL8 (0.35) ALDH1A1
SCHEMBL3232439 0.77 ALDH1A1 (0.47) ALDH1A1GAAGFERCYP4F2CYP4A11
SCHEMBL21617916 0.72 ALDH1A1 (0.44) ACLYALDH1A1GAAGFERCYP4F2
SCHEMBL7039256 0.71 LMNA (0.38) ACLYALDH1A1TSHRNPC1RAB9A
SCHEMBL8298121 0.71 ALDH1A1 (0.33) ALDH1A1HPGDKMT2A
SCHEMBL17072002 0.71 ACLY (0.42) ACLYALDH1A1GAAGFERCYP4F2
SCHEMBL480112 0.71 MEN1 (0.44) ACLYALDH1A1CYP4F2CYP4A11SMN1; SMN2
SCHEMBL377862 0.69 CYP4F2 (0.51) ALDH1A1GAAGFERCYP4F2CYP4A11
SCHEMBL6302782 0.69 PDGFRB (0.33) ALDH1A1GAAGFERHSP90AB1RAB9A
SCHEMBL2970186 0.69 ALDH1A1 (0.47) ALDH1A1GAAGFERCYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0882029-B1 HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS MERCK & CO INC (US) 2003-04-02 EP disclosed
US-6090836-A DIETETICS; ADJUSTMENT OF TRIGLYCERIDE CONCENTRATION MERCK & CO., INC. (US) 2000-07-18 US disclosed
EP-1011651-A4 METHOD OF TREATING DIABETES AND RELATED DISEASE STATES MERCK & CO INC (US) 2000-06-28 EP disclosed
EP-1011651-A1 METHOD OF TREATING DIABETES AND RELATED DISEASE STATES Merck & Co., Inc. (US) 2000-06-28 EP disclosed
EP-0882029-A1 HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS Merck & Co., Inc. (US) 1998-12-09 EP disclosed
WO-1997027847-A1 METHOD OF TREATING DIABETES AND RELATED DISEASE STATES MERCK & CO., INC. (US) 1997-08-07 WO disclosed
WO-1997028137-A1 HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS MERCK & CO., INC. (US) 1997-08-07 WO disclosed